1492 Capital Management’s TherapeuticsMD TXMD Stock Holding History

1492 Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,367	Closed	-$767K	–	102
2019 Q4	$767K	Sell	6,367 -779	-11%	-$112K	0.68%	42
2019 Q3	$1.3M	Sell	7,146 -5,870	-45%	-$827K	1.26%	28
2019 Q2	$1.69M	Sell	13,016 -68	-0.5%	-$12.2K	1.58%	21
2019 Q1	$3.19M	Sell	13,084 -913	-7%	-$242K	2.7%	10
2018 Q4	$2.67M	Buy	13,997 +6,636	+90%	+$1.62M	2.39%	14
2018 Q3	$2.41M	Sell	7,361 -29	-0.4%	-$8.88K	1.57%	24
2018 Q2	$2.31M	Sell	7,390 -55	-0.7%	-$16.8K	1.65%	24
2018 Q1	$1.81M	Sell	7,445 -306	-4%	-$85.8K	1.39%	27
2017 Q4	$2.34M	Sell	7,751 -63	-0.8%	-$17.5K	1.83%	21
2017 Q3	$2.07M	Buy	7,814 +3,622	+86%	+$1.05M	1.83%	20
2017 Q2	$1.1M	Sell	4,192 -258	-6%	-$64.6K	0.97%	34
2017 Q1	$1.6M	Sell	4,450 -947	-18%	-$293K	1.25%	28
2016 Q4	$1.56M	Buy	5,397 +4,692	+666%	+$1.45M	1.2%	30
2016 Q3	$240K	Sell	705 -45	-6%	-$16.4K	0.2%	85
2016 Q2	$319K	Sell	750 -73	-9%	-$30.1K	0.29%	72
2016 Q1	$263K	Buy	823 +186	+29%	+$63.5K	0.22%	82
2015 Q4	$330K	Buy	+637	New	+$235K	0.24%	79

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

1492 Capital Management's TXMD Position: Q1 2020 in Review

1492 Capital Management sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 6,367 shares — an estimated $767K sold.

1492 Capital Management first reported a position in TXMD in Q4 2015 and held it in 17 quarters. The position peaked at $3.19M in Q1 2019. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

1492 Capital Management reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
1492 Capital Management sold 6,367 TherapeuticsMD shares in Q1 2020, an estimated $767K.
1492 Capital Management first reported a position in TherapeuticsMD in Q4 2015 and held it in 17 quarters.
1492 Capital Management's TherapeuticsMD position peaked at $3.19M in Q1 2019.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on 1492 Capital Management's 13F filing for Q1 2020, filed 12 May 2020.